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Rationale for Protocol 
Review 
 
1. Takes advantage of new technical information gleaned from 
evolving database of scientific literature. 
2. Considers written comments from stakeholders (i.e., RMDs, 
laboratories, patient advocates, government officials).  
3. Incorporates feedback from listening sessions with labs and 
RMDs.    
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Overview of Proposed Changes 
 
1. Adopt new Heavy Metal Limits consistent with United States 
Pharmacopeia (USP) upper concentration limits  
2. Increase the Residual Solvent Limits to bring them in 
alignment with USP concentration limits 
3. Require product labeling to specify the amount of product 
that has been evaluated as safe for consumption (i.e., 0.35 
oz. or 10 g/day) 
4. Require product labeling to specify the route of exposure 
that the product has been evaluated for (i.e., ingestion only; 
all other uses)     
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Original Approach 
• Based upon AHP standards for herbal 
supplements  
• Based upon “risk assessment” worst 
case scenario  
• Assumption of 28.4 g/day of plant 
material consumed 
• Route of exposure not specified and 
thus inclusive of all routes 
• No labeling requirement.  Approach 
very conservative/protective. 
  
Proposed Approach 
• Based upon USP standards for drugs 
and nutritional supplements 
• Reasonable Maximum Exposure 
(RME) assumptions based on usage  
• Sets exposure to 10 g/day based on 
review of a dozen credible studies 
• 2 sets of standards: ingestion, all 
routes (ingestion, inhalation, and 
dermal) 
• Labeling specifies both safe amount 
of exposure product is tested safe for 
and route of consumption 
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Approach Comparison 
Benefits of Proposed Approach 
 
• By moving to USP standard, DPH references “living levels” that are 
consistently revised and based upon evolving science, analytical 
capabilities, and other new information  
• More versatile as route of exposure yields two different maximum levels 
thus tailoring levels to product type 
• Similar to recommended daily dosage labeling on medications thus 
emphasizing the importance of patient ownership 
• Consistent with approach used by FDA compliant evaluation of drugs, 
medical devices and supplements 
• Detailed product labeling specifies the amount of product that has been 
evaluated as safe as well as route of exposure evaluated for 
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Timeline 
 
• November 19, 2015:  Proposed Protocols released 
– Posted on DPH website 
– Public Comment period begins 
– Current Protocols and Waiver process remain in effect 
• December 17, 2015:  Public Comment Period ends 
– DPH assesses feedback, reserves right to follow-up with requests for 
additional information 
• January 11, 2015:  Anticipated date for Final Protocol release 
– Posted on DPH website 
• March 31, 2015:  Anticipated date Protocols become effective 
– Testing results held to new levels based on USP standards 
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Public Comment Period 
 
• DPH welcomes and encourages feedback 
– Email comments to RMDCompliance@state.ma.us 
– Mail comments to Program (address on last slide) 
• DPH available for technical questions 
– Email comments to RMDCompliance@state.ma.us 
– Priority will be placed on timely response 
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Public comments and technical questions should be 
directed to:   
 
Via Email:  RMDCompliance@state.ma.us. 
 
Via Mail:   Medical Use of Marijuana Program 
    Attn:  RMD Compliance   
    99 Chauncy St., 11th Floor 
    Boston, MA  02111 
 
